Healthcare stocks were declining pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.7% lower and the iShares Biotechnology ETF (IBB) down 0.5%.
Novo Nordisk (NVO) said China's National Medical Products Administration has accepted its marketing application for the oral version of its weight-loss drug Wegovy, Reuters reported. Novo Nordisk stock was down more than 2% premarket.